Akero Therapeutics

Organization Address
1 Sansome Street, Suite 3630
San Francisco, CA 94104


Biotech and Pharmaceutical

Drug Discovery and Development

Organization Description

Akero Therapeutics is committed to providing meaningful treatment options for people with
serious metabolic diseases like non-alcoholic steatohepatitis (NASH), a disease marked by
inflammation in the liver and liver cell damage resulting in fibrosis, cirrhosis, liver failure and
death. Over the past decade, scientists have determined that the endogenous hormone fibroblast
growth factor 21 (FGF21) plays a critical role in the regulation of metabolism and signaling
throughout the body, acting on multiple organ systems, including the liver. The body naturally
recruits FGF21 to restore health to distressed organs and ensure balance across metabolic
pathways. Akero’s lead clinical program, AKR-001 is a novel, long-acting Fc fusion modified
FGF21 agonist and potential best-in-class treatment for NASH. AKR-001 builds upon two
decades of work on FGF21 biology and is designed to affect both the liver and adipose tissue,
reducing liver fat and suppressing inflammation and fibrosis.